Vast is a preclinical airway immunology company focused on breaking the vicious cycle of infection and chronic inflammation in respiratory diseases. We live at the air-liquid interface in efforts to advance new treatments for some of the world’s most challenging drug-resistant microbial infections.
The Vast technology platform begins with the unmatched antimicrobial activity of nitric oxide in the form of stable prodrugs. When our new chemical entities are combined with inhalation formulation expertise and proprietary chemistry for delivering drug candidates to the lungs, the result is aerosolized therapies targeting the specific needs of individual patient populations.
Nitric oxide is an endogenous molecule that plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.
Learn about our team.